Gilead Sciences, a leading pharmaceutical company, has just made a big investment in a new type of treatment for immune system diseases. The company is paying $2 billion to acquire Ouro Medicines, a smaller biotech company. As part of this deal, Gilead gains access to a promising experimental drug called OM336, also known as gamgertamig. This drug is designed to work in a unique way by targeting both B cells and T cells in the immune system, which could make it a first-choice treatment for certain diseases.
Gilead will pay $1.675 billion upfront, with the possibility of paying another $500 million later if the drug meets specific development and sales goals. The drug is currently in early stages of testing (Phase I/II) and has already shown impressive results in a trial for a rare, severe immune disease. In this trial, a single treatment cycle of OM336 led to significant improvement and a good safety profile.
Dr. Dietmar Berger, Gilead’s Chief Medical Officer, explained that OM336 works by targeting a specific protein called BCMA, which is found on B cells. This approach is different from existing treatments and could provide long-lasting control of the disease. He said, ‘BCMA is a proven target, and early data shows that this type of treatment could revolutionize how we manage autoimmune diseases. This fits perfectly with our goal to develop innovative treatments that could change the standards of care.’
Gilead and another company, Galapagos, plan to work together on developing OM336 as part of this acquisition. The deal still needs to meet standard conditions before it can be finalized.
This news comes at a time when other major pharmaceutical companies are also investing in similar treatments. For example, Sanofi recently secured rights to another T cell engager, called KT501, through a licensing agreement with Kali Therapeutics. Sanofi agreed to pay up to $1.05 billion if the drug meets development and sales milestones. The CEO of Kali Therapeutics, Weihao Xu, believes that KT501 could address unmet needs in autoimmune diseases by effectively reducing harmful B cell populations while minimizing side effects like excessive immune reactions.
This is an exciting time for patients with immune-mediated diseases, as these new treatments could offer more effective and safer options in the future.